Lobbying Filing Details

Total Spending

$604,408

Activities

5

Lobbyists

5

Gov't Entities

40

Filing Information
Filing UUID:
18e63aee-4dcb-4563-b8e5-8f851921a624
Type:
Q4 - 4th Quarter - Report
Period:
2013 - 4th Quarter (Oct 1 - Dec 31)
Date Posted:
January 21, 2014 at 4:51 PM
Income:
$0
Expenses:
$604,408
Expense Method:
Method C - Reporting amounts under section 162(e) of the Internal Revenue Code
Document URL:
View Submission
Quick Info
  • Document Type: text/html
  • Posted By: Melissa Schulman, Senior Vice President Government Affairs
Registrant
ASSOCIATION FOR ACCESSIBLE MEDICINES

Association representing the interests of the generic pharmaceutical industry.

Washington, District of Columbia
Client
ASSOCIATION FOR ACCESSIBLE MEDICINES
District of Columbia, United States of America
Lobbying Activities (5)
Activity 1
Budget/Appropriations

Bills: H. Con. Res. 25 - Establishing the budget for the United States Government for fiscal year 2014 and setting forth appropriate budgetary levels for fiscal years 2015 through 2023; H.R. 2725 FDA Safety over Sequestration Act; H.J. Res 59 Continuing Appropriations Resolution 2014; S 1413 FDA User Fee Protection Act; HR 2410 Agriculture, Rural Development, Food Drug Administration Appropriations Act 2014;S 1244 Agriculture, Rural Development, Food Drug Administration Appropriations Act 2014
FY 2014 Budget

Lobbyists (4)
  • MR. JASON R MONEY
  • MR. CHRISTOPHER DAVIS
  • MELISSA SCHULMAN
  • HEIDI WILSON
Government Entities (8)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • Government Accountability Office (GAO)
  • Congressional Budget Office (CBO)
  • Health & Human Services, Dept of (HHS)
  • ... and 3 more
Activity 2
Copyright/Patent/Trademark

S. 214 - Preserve Access to Affordable Generics Act; S.504 - Fair and Immediate Release of Generic Drugs Act, H.R. 3309 Innovation Act, HR 3709 Protecting Consumers Access to Generic Drugs Act of 2013

Lobbyists (4)
  • MR. JASON R MONEY
  • MR. CHRISTOPHER DAVIS
  • MELISSA SCHULMAN
  • HEIDI WILSON
Government Entities (8)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • Government Accountability Office (GAO)
  • Congressional Budget Office (CBO)
  • Health & Human Services, Dept of (HHS)
  • ... and 3 more
Activity 3
Medicare/Medicaid

Implementation of Health Care Reform, Medicaid Rebates, Prescription Drug Reimbursement, Medicare Part D ProgramH. Con. Res. 25 - Establishing the budget for the United States Government for fiscal year 2014 and setting forth appropriate budgetary levels for fiscal years 2015 through 2023
H.R. 1588 - Medicare Drug Savings Act of 2013
S.740 - Medicare Drug Savings Act of 2013
S. 1871 SGR Repeal and Medicare Beneficiary Access Act of 2013

Lobbyists (4)
  • MR. JASON R MONEY
  • MR. CHRISTOPHER DAVIS
  • MELISSA SCHULMAN
  • HEIDI WILSON
Government Entities (8)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • Government Accountability Office (GAO)
  • Congressional Budget Office (CBO)
  • Health & Human Services, Dept of (HHS)
  • ... and 3 more
Activity 4
Pharmacy

Implementation of Health Care Reform, Implementation of Generic Biologics, Counterfeit Drugs/Import Safety, Prescription Drug Importation/Re-Importation, Drug Shortages, Labeling of Generic Drugs, Risk Evaluation Mitigation Strategies, Biosimilar NamingH.R.486 - Stop Tampering of Prescription Pills Act of 2013
H.R.1285 - To amend the Controlled Substances Act to make any substance containing hydrocodone a schedule II drug.
H.R. 1919 - Safeguarding America's Pharmaceuticals Act of 2013
H.R.1958 - Gray Market Drug Reform and Transparency Act of 2013
H.R.2186 - VALID Compounding Act of 2013
H.R. 2725 FDA Safety over Sequestration Act
H.R. 3019 SAFE Compounded Drugs Act
H.R. 3089 Compounding Clarity Act of 2013
H.R. 3204 Drug Quality and Security Act
H.R. 3709 Protecting Consumers Access to Generic Drugs Act of 2013
H. Con. Res. 25 - Establishing the budget for the United States Government for fiscal year 2014 and setting forth appropriate budgetary levels for fiscal years 2015 through 2023
H Res - 161 Expressing the sense of the House of Representatives that the Food and Drug Administration should encourage the use of abuse-deterrent formulations of drugs
S.214 - Preserve Access to Affordable Generics Act
S.504 - Fair and Immediate Release of Generic Drugs Act
S.621 - Safe Prescribing Act of 2013
S 957 - Drug Supply Chain Security Act
S 959 - Pharmaceutical Quality, Security, and Accountability Act

Lobbyists (5)
  • MR. JASON R MONEY
  • MR. CHRISTOPHER DAVIS
  • CHRISTINE SIMMON
  • MELISSA SCHULMAN
  • HEIDI WILSON
Government Entities (8)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • Government Accountability Office (GAO)
  • Congressional Budget Office (CBO)
  • Health & Human Services, Dept of (HHS)
  • ... and 3 more
Activity 5
Trade (domestic/foreign)

Free Trade Agreements-Trans Pacific Partnership

Lobbyists (3)
  • MR. JASON R MONEY
  • MR. CHRISTOPHER DAVIS
  • MELISSA SCHULMAN
Government Entities (8)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • Government Accountability Office (GAO)
  • Congressional Budget Office (CBO)
  • Health & Human Services, Dept of (HHS)
  • ... and 3 more

Source: LDA.gov, data retrieved November 4, 2026. FilingExplorer is not affiliated with LDA.gov; the Senate Office of Public Records cannot vouch for data or analyses derived from these records after retrieval.